Many derivatives of testosterone have been synthesized which in man promote weight gain and a positive nitrogen and calcium balance in doses that cause relatively little evidence of androgen action. In rats these preparations cause an increase inthe weight of the levator ani muscle which is said to constitute a "myotrophic" effect. In theory such hormones might be expected to improve the state of severely-affected rheumatoid arthritic patients receiving long-term prednisolone therapy. The improvements that might occur would be:
(1) An improvement in deficient musculature that might be reflected in an improved functional capacity and increased strength of grip; (2) A decreased incidence of, or reversal of, osteoporosis that could be looked for in lateral radiographs of the lumbar spine; (3) A decrease in the atrophy of skin which is clinically manifest in "pathological bruising" of the limbs and senile type "purpura" of the forearms and hands. If the "anabolic" hormone had any effect upon the disease process itself, this might be detectable in the erythrocyte sedimentation rate, the haemoglobin concentration, and the changes observed in radiographs of hands and feet. This report is of a double-blind trial of methenolone acetate (Primobolan) 
The Patients
The criteria for admission to the trial were:
(1) The subjects were to be ambulant females only, of age 20 to 65 years, weighing less than 75 kg. (2) The duration of prednisolone or equivalent therapy was to have been at least 1 year at a mean dose of 7-5 to 12-5 mg./day. (3) The patients should not be suffering from any disorder thought likely to interfere with the interpretation of the trial.
Allocation
Particulars of patients considered suitable for the trial were sent to the statistician (Dr. Lewis-Faning) who put them into four groups: pre-menopausal and postmenopausal with previous corticosteroid therapy of less than or more than 4 years. Within each group he allocated tablets "x" or "y" at random.
Procedure
Forms were provided for entry details, for records at weeks 0, 8, 16, 24, 32, 40, and 48 , and for a final summary and comment. Each form was sent, on completion, to the statistician. Radiographs of the hands, feet, and lateral lumbar spine were taken, and the sheep cell agglutination or latex-fixation tests performed, at the start and at the end of the trial year.
Results
The findings were analysed in detail by the statistician who alone knew which was the active tablet until the last patient had completed 1 year in the trial. Much of the detail proved to be noncontributory and will be omitted from the findings given below.
( (4) Skin-fold Thickness.-An attempt was made to find out whether any increase in weight that might occur was due to increased fat deposition. This was done by estimating the thickness of subcutaneous fat with Verel calipers. Two sites were used, the middle third of the back of the left arm and just below the left scapula.
The arm measurement for the treated group fell from 1 -57 to 1 -25 cm., whereas the control group fell only from 1 -7 to 1 -65 cm. The end of year figures are significantly different.
The back measurements showed the reverse trend; the treated group measurement rose from 0 98 to 1 -18 cm., whereas those for the control group fell from 1-31 to 1-28 cm.
A study of all the measurements made at each assessment period revealed some instances of changes One was found to be present before the trial and not to have changed during the trial.
One was found to have occurred during the trial. The third occurred during the trial according to the hospital reader, but was considered only to have increased during the trial by the independent reader.
One can only conclude from these findings that there was no radiographic evidence to suggest that the methenolone therapy was beneficial.
(11) Analgesics.-The use of analgesics was recorded. Only two patients were noted as having none. The numbers and types of analgesics taken by each group were similar and remained practically constant throughout the year. The majority in each group took some form of aspirin three or four times a day.
(12) Clinical Assessments of "functional capacity" and pathological bruising.-Analysis of the records of the former showed that the percentage of improvement (actual of possible) and the percentage of deterioration (actual of possible) for the two groups did not differ significantly. Some evidence of pathological bruising was recorded for 80 per cent. of the patients. The impressions given of improvement and deterioration were the same for each group.
(13) Side-Effects.-The only side-effect that was peculiar to the treated group was acne, which was reported by four patients (10 per cent.). As physicians were not asked to state whether acne was present or not, it is likely that 10 per cent. is an under-estimate of the frequency of this side-effect.
Discussion
That the treated group did receive an "anabolic" hormone is apparent from the occurrence of acne and the significant weight increase. The apparent increase in back skin-fold thickness at the expense of arm skin-fold thickness may also reflect the action of an "anabolic" hormone.
The only statistically significant improvement noted was in the haemoglobin concentration of the treated group in the last 4 months.
These findings are disappointing so far as a hoped-for benefit from the anabolic hormone is concerned, but the documentation of objective assessments for a year in a defined group of rheumatoid arthritic patients receiving long-term prednisolone therapy is of interest and of value as a yardstick for other trials. One observation made is of particular interest, namely the small number of new bone erosions noted. This finding is in agreement with that of the Prednisolone/Analgesic Trial of the Joint Committee of the Medical Research Council and Nuffield Foundation (1959) , and contrasts markedly with the evidence of bone erosion in patients not treated with prednisolone in that trial and in both the E.R.C. Cortisone/Aspirin Trial (1957) and the E.R.C. Gold Therapy Trial (1960) . This finding may have a bearing on the mode of action of small doses of prednisolone, as was pointed out by West (1962). Summary A double-blind controlled trial was made of methenolone acetate, 5 mg. twice daily by mouth, in the treatment of female rheumatoid arthritic patients who were receiving long-term prednisolone therapy; 58 patients completed 1 year, 34 on methenolone and 24 controls. The two groups were well matched in respect of age, menopausal status, weight, skin-fold thickness, duration of rheumatoid arthritis, duration of prednisolone therapy, E.S.R., Hb concentration, S.C.A.T. or latex-fixation tests, strength of grip, and functional capacity. There was no evidence that the patients who left the trial significantly affected the comparability of the groups or the eventual findings. The only statistically significant differences found between the groups was an increase in weight in the first 8 weeks and a rise in haemoglobin concentration in the last 24 weeksboth in the treated group. The trends of change in skin-fold thickness suggested that the methenolonetreated group had an increase in fat deposition below the scapula and a decrease at the back of the arm. No significant difference was found in the radiographic changes observed in hands, feet, and lumbar spine. The only side-effect peculiar to the treated group was acne (in 10 per cent.). menopausique, le poids, I'6paisseur du pli cutane, la duree de l'arthrite rhumatismale, la dur6e de la therapie a la prednisolone, la sedimentation globulaire, le taux de l'hemoglobine, la reaction de Waaler-Rose ou de fixation du latex, la force de la main et la capacite fonctionnelle. Rien n'indiquait que les malades qui avaient abandonne l'essai aient affecte appreciablement la comparabilite des groupes ou les resultats eventuels.
On n'a trouve que deux differences statistiquement significatives entre ces deux groupes: une augmentation du poids pendant les premieres huit semaines et une elevation du taux de l'hemoglobine pendant les dernieres vingt-quatre semaines dans le groupe traite. La mesure de l'epaisseur du pli cutane indiquait que dans le groupe traite par le methenolone les dep6ts graisseux sous l'epaule tendaient a augmenter et ceux a la partie dorsale du bras a diminuer. On n'a pas trouve de difference significative en ce qui concerne l'image radiographique des mains, des pieds et de l'epine lombaire. Le seul effet secondaire particulier au groupe traite etait l'acne (en 10 pour cent des cas).
Investigacion controlada del acetato de metenolona en enfermas con artritis reumatoide tratadas con prednisolona SUMARTO Una investigaci6n controlada, double-blind fue emprendida con el acetato de metenolona, 5 mg. dos veces al dia por la via oral en el tratamiento de enfermas con artritis reumatoide, y sometidas a la terapia prolongada con prednisolona; 58 enfermas completaron un anio de esta investigaci6n, 34 de ellas tomando la metenolona y las demAs 24 sirviendo de testigos. Los dos grupos diferian poco entre si respecto a la edad, estado menopausico, peso, espesor del pliegue cutaneo, duracion de la artritis reumatoide, duracion de la terapia con prednisolona, velocidad de sedimentaci6n eritrocitaria, cifras de hemoglobina, reaccion de Waaler-Rose o de fijaci6n del latex, fuerza de la mano y capacidad funcional. No se encontr6 evidencia alguna de que las enfermas que dejaron de participar en el ensayo hubiesen podido afectar apreciadamente la comparabilidad de los grupos o los resultados finales.
Se encontraron s6lo dos diferencias estadisticamente significativas entre estos grupos: un aumento de peso en las primeras ocho semanas y de la hemoglobina en las ultimas 24 semanas-ambas en el grupo tratado. La medicion del pliegue cutaneo indic6 que en el grupo tratado por la metenolona los depositos adiposos tendian a aumentar debajo de la espalda y a disminuir en la parte dorsal del brazo. No se encontr6 diferencia significativa en las alteraciones radiogrificas de las manos, de los pies y de la columna lumbar. El uinico efecto secundario particular en el grupo tradado fu6 el acne (en un 10 por ciento de los casos). 
